The innate immune system in SLE: type I interferons and dendritic cells

Abstract

Patients with systemic lupus erythematosus (SLE) have an increased expression of type I interferon (IFN) regulated genes because of a continuous production of IFN-α. The cellular and molecular background to this IFN-α production has started to be elucidated during the last years, as well as the consequences for the innate and adaptive immune systems. Plasmacytoid dendritic cells (pDC) activated by immune complexes containing nucleic acids secrete type I IFN in SLE. Type I IFN causes differentiation of monocytes to myeloid-derived dendritic cell (mDC) and activation of autoreactive T and B cells. A new therapeutic option in patients with SLE is, therefore, inhibition of IFN-α, and recent data from a phase I clinical trial suggests that administration of neutralizing monoclonal antibodies against anti-IFN-α can ameliorate disease activity.

Get full access to this article

View all access options for this article.

References

1 Hardy MP Owczarek CM Jermiin LS Ejdeback M Hertzog PJ . Characterization of the type I interferon locus and identification of novel genes. Genomics 2004; 84: 331 – 345 .

2 Akira SS Uematsu S Takeuchi O . Pathogen recognition and innate immunity. Cell 2006; 124: 783 – 801 .

3 Takaoka A Wang Z Choi MK . DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007; 448: 501 – 505 .

4 Siegal FP Kadowaki N Shodell M . The nature of the principal type 1 interferon-producing cells in human blood. Science 1999; 284: 1835 – 1837 .

5 Fitzgerald-Bocarsly P Feng D . The role of type I interferon production by dendritic cells in host defense. Biochimie 2007; 89: 843 – 855 .

6 Theofilopoulos AN Baccala R Beutler B Kono DH . Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005; 23: 307 – 336 .

7 Banchereau J Steinman RM . Dendritic cells and the control of immunity. Nature 1998; 392: 245 – 252 .

8 Steinman RM Banchereau J . Taking dendritic cells into medicine. Nature 2007; 449: 419 – 426 .

9 Kadowaki N Ho S Antonenko S . Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194: 863 – 869 .

10.

10 Janeway CA Yagi J Conrad PJ . T-cell responses to Mls and to bacterial proteins that mimic its behavior. Immunol Rev 1989; 107: 61 – 88 .

11.

11 Medzhitov R Janeway CA . Decoding the patterns of self and nonself by the innate immune system. Science 2002; 296: 298 – 300 .

12.

12 Ueno H Klechevsky E Morita R . Dendritic cell subsets in health and disease. Immunol Rev 2007; 219: 118 – 142 .

13.

13 Gallucci S Lolkema M Matzinger P . Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999; 5: 1249 – 1255 .

14.

14 Sauter B Albert ML Francisco L Larsson M Somersan S Bhardwaj N . Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000; 191: 423 – 434 .

15.

15 Seong SY Matzinger P . Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004; 4: 469 – 478 .

16.

16 Steinman RM Nussenzweig MC . Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Nat Acad Sci U S A 2002; 99: 351 – 358 .

17.

17 Banchereau J Pascual V . Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006; 25: 383 – 392 .

18.

18 Bengtsson A Sturfelt G Truedsson L . Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not antiretroviral antibodies. Lupus 2000; 9: 664 – 671 .

19.

19 Bennett L Palucka AK Arce E . Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711 – 723 .

20.

20 Baechler EC Batliwalla FM Karypis G . Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003; 100: 2610 – 2615 .

21.

21 Blomberg S Eloranta ML Cederblad B Nordlind K Alm GV Rönnblom L . Presence of cutaneous interferon-a producing cells in patients with systemic lupus erythematosus. Lupus 2001; 10: 484 – 490 .

22.

22 Rönnblom L Eloranta ML Alm GV . The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 408 – 420 .

23.

23 Lövgren T Eloranta ML Båve U Alm GV Rönnblom L . Induction of interferon-a production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004; 50: 1861 – 1872 .

24.

24 Lövgren T Eloranta ML Kastner B Wahren-Herlenius M Alm GV Rönnblom L . Induction of interferon-a by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjögren's syndrome autoantigen-associated RNA. Arthritis Rheum 2006; 54: 1917 – 1927 .

25.

25 Tian J Avalos AM Mao SY . Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007; 8: 487 – 496 .

26.

26 Sigurdsson S Nordmark G Göring HH . Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 2005; 76: 528 – 537 .

27.

27 Schindler C Levy DE Decker T . JAK–STAT signaling: from interferons to cytokines. J Biol Chem 2007; 282: 20059 – 20063 .

28.

28 Remmers EF Pleng RM Lee AT . STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007; 357: 977 – 986 .

29.

29 Kaplan MH . STAT4: a critical regulator of inflammation in vivo. Immunol Res 2005; 31: 231 – 242 .

30.

30 Hu G Mancl ME Barnes BJ . Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death. Cancer Res 2005; 65: 7403 – 7412 .

31.

31 Blanco P Palucka AK Gill M Pascual V Banchereau J . Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001; 294: 1540 – 1543 .

32.

32 Blanco P Pitard V Viallard JF Taupin JL Pellegrin JL Moreau JF . Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52: 201 – 211 .

33.

33 Le Bon A Thompson C Kamphuis E . Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol 2006; 176: 2074 – 2078 .

34.

34 Litinskiy MB Nardelli B Hilbert DM . DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002; 3: 822 – 829 .

35.

35 Jego G Palucka AK Blanck JP Chalouni C Pascual V Banchereau J . Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003; 19: 225 – 234 .

36.

36 Means TK Latz E Hayashi F Murali MR Golenbock DT Luster AD . Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005; 115: 407 – 417 .

37.

37 Bave U Magnusson M Eloranta ML Perers A Alm GV Ronnblom L . FcgRIIa is expressed on natural IFN-a-producing cells (plasmacytoid dendritic cells) and is required for the IFN-a production induced by apoptotic cells combined with lupus IgG. J Immunol 2003; 171: 3296 – 3302 .

38.

38 Lauwerys BR Wakeland EK . Genetics of lupus nephritis. Lupus 2005; 14: 2 – 12 .

39.

39 Yurasov S Wardemann H Hammersen J . Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005; 201: 703 – 711 .

40.

40 Lebon P . Inhibition of herpes simplex virus type 1-induced interferon synthesis by monoclonal antibodies against viral glycoprotein D and by lysosomotropic drugs. J Gen Virol 1985; 66: 2781 – 2786 .

41.

41 Santiago-Raber ML Baccala R Haraldsson KM . Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003; 197: 777 – 788 .

42.

42 Braun D Geraldes P Demengeot J . Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun 2003; 20: 15 – 25 .

43.

43 Wallac DJ Petri M Olsen N . MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus. Arthritis Rheum 2007; 56: S526 – S527 [Abstract 1325].

44.

44 Blomberg S Eloranta ML Magnusson M Alm GV Rönnblom L . Expression of the markers BDCA-2 and -4 and production of interferon-a by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Rheum 2003; 48: 2524 – 2532 .

45.

45 Lafyatis R Marshak-Rothstein A . Toll-like receptors and innate immune responses in systemic lupus erythematosus. Arthritis Res Ther 2007; 9: 222 – 228 .